Vitrolife AB

Vitrolife announces the resignation of CEO Bronwyn Brophy O’Connor, who is taking a CEO role in another area of medical technology. She will remain in office during a notice period of up to 12 months to ensure an orderly transition. The board of directors has begun the search for a successor and is considering internal and external candidates. » Más en de.investing.com

Vitrolife reported Q1 2026 EPS of SEK 0.74 and revenue of SEK 807 million, both slightly below analyst expectations. Organic growth in local currency was 5%, while currency effects reduced reported revenue by 4%. Gross margin improved to 59.9% and EBITDA rose 4.6%, supported by higher‑margin products and growth in the Americas and APAC. Despite the figures, the stock climbed 6.97% in pre‑market trading, supported by a robust product pipeline and planned product launches. » Más en de.investing.com

Vitrolife reported Q1 2026 sales of SEK 807m (–4% reported, +5% organic) and a gross margin of 59.9% thanks to a product-mix shift. EBITDA was SEK 251m (margin 31.1%), earnings per share were SEK 0.74, slightly below consensus. The Americas grew organically by 11%, APAC recovered by 7%, while EMEA was weighed down by the crisis in the Middle East. Operating cash flow rose strongly to SEK 172m, the dividend is to remain SEK 1.10, and management expects further margin improvements from restructuring and product launches. » Más en de.investing.com